Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
|
SE |
|
Credit Agricole SA
OTC:CRARF
|
FR |
|
M
|
MFA Financial Inc
F:M4Z
|
US |
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs. Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income. What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs.
Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income.
What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.
Strong start: Sobi said Q1 was a very strong start to 2026, with revenue up 24% at constant exchange rates and adjusted EBITA up to a 38% margin, driven by broad-based portfolio growth.
Launch momentum: The company highlighted six major launches and said its strategic portfolio now represents 63% of revenue, with standout performance from Altuvoct, Gamifant, Aspaveli and Doptelet.
Aspaveli surprise: Management said Aspaveli’s nephrology launch in Europe is tracking ahead of internal expectations, with strong physician feedback and early uptake in C3G and IC-MPGN.
Guidance held: Full-year 2026 guidance was unchanged, with revenue expected to grow at low double-digit percentage at constant exchange rates and adjusted EBITA margin expected in the mid-30s.
Pipeline progress: Sobi pointed to important upcoming milestones, including the FDA decision on NASP in June, first Pozdeutinurad data by end of Q2, and continued regulatory steps for Tryngolza and Gamifant.
